Literature DB >> 25256776

Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?

Klaus Pors1, Jan S Moreb2.   

Abstract

Aldehyde dehydrogenases (ALDHs) belong to a superfamily of 19 isozymes that are known to participate in many physiologically important biosynthetic processes including detoxification of specific endogenous and exogenous aldehyde substrates. The high expression levels of an emerging number of ALDHs in various cancer tissues suggest that these enzymes have pivotal roles in cancer cell survival and progression. Mapping out the heterogeneity of tumours and their cancer stem cell (CSC) component will be key to successful design of strategies involving therapeutics that are targeted against specific ALDH isozymes. This review summarises recent progress in ALDH-focused cancer research and discovery of small-molecule-based inhibitors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25256776     DOI： 10.1016/j.drudis.2014.09.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  48 in total

1.  Inhibition, crystal structures, and in-solution oligomeric structure of aldehyde dehydrogenase 9A1.

Authors:  Jesse W Wyatt; David A Korasick; Insaf A Qureshi; Ashley C Campbell; Kent S Gates; John J Tanner
Journal:  Arch Biochem Biophys       Date:  2020-07-24       Impact factor: 4.013

2.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.

Authors:  David W Clark; Komaraiah Palle
Journal:  Ann Transl Med       Date:  2016-12

3.  Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.

Authors:  Xinwei Yun; Keqiang Zhang; Jinhui Wang; Rajendra P Pangeni; Lu Yang; Melissa Bonner; Jun Wu; Jami Wang; Isaac K Nardi; Ming Gao; Dan J Raz
Journal:  Mol Cancer Res       Date:  2018-05-02       Impact factor: 5.852

4.  Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer.

Authors:  M Martín; A Hinojar; L Cerezo; J García; M Lopez; J Prada; A Marín; C Gamallo
Journal:  Clin Transl Oncol       Date:  2015-11-16       Impact factor: 3.405

5.  Covalent Modification of the Flavin in Proline Dehydrogenase by Thiazolidine-2-Carboxylate.

Authors:  Ashley C Campbell; Donald F Becker; Kent S Gates; John J Tanner
Journal:  ACS Chem Biol       Date:  2020-03-18       Impact factor: 5.100

Review 6.  Cancer stem cells as targets for immunotherapy.

Authors:  Amy S Codd; Takayuki Kanaseki; Toshihiko Torigo; Zsuzsanna Tabi
Journal:  Immunology       Date:  2017-12-18       Impact factor: 7.397

Review 7.  Immune targeting of cancer stem cells in gastrointestinal oncology.

Authors:  Robert J Canter; Steven K Grossenbacher; Erik Ames; William J Murphy
Journal:  J Gastrointest Oncol       Date:  2016-04

8.  Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.

Authors:  Xiaoli Wang; Cing Siang Hu; Bruce Petersen; Jiajing Qiu; Fei Ye; Jane Houldsworth; Kevin Eng; Fei Huang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-09-25

9.  The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.

Authors:  Maria A Voronkova; Liying W Rojanasakul; Chayanin Kiratipaiboon; Yon Rojanasakul
Journal:  Mol Cell Biol       Date:  2020-01-03       Impact factor: 4.272

10.  Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Cameron D Buchman; Mikhail Chtcherbinine; Bikash Debnath; Pooja Mehta; Kun Yang; Cynthia A Morgan; Siwei Li; Jeremy Felton; Duxin Sun; Geeta Mehta; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  J Med Chem       Date:  2018-09-28       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.